Knight Therapeutics reports Q3 EPS (C$0.04) vs. (C$0.00) last year

Reports Q3 revenue C$121.5M vs. C$92.3M last year. “I am pleased to announce that for the first nine months of 2025, we achieved record-high adjusted revenues of $319 million and adjusted EBITDA of approximately $49 million. These record results underscore the successful integration of the Paladin and Sumitomo portfolios, which strengthened our Canadian operations and drove meaningful contribution. In addition, our innovative promoted product portfolio delivered 12% of organic growth on a constant currency basis. Beyond financial performance, we advanced and expanded our pipeline with the launches of Jornay PM in Canada, Minjuvi in Argentina and Pemazyre in Brazil and Mexico and strengthened our partnership with Incyte by adding retifanlimab and axatilimab. While we experienced regulatory setbacks for Qelbree in Canada and Tavalisse in Brazil, we will respond to the agencies’ requests and expect to bring these drugs to market. In addition, subsequent to quarter-end, we doubled the size of our revolving credit facility to US$100 million with an accordion feature of an additional US$100 million. This facility provides us with the financial flexibility to continue to transact and grow our business.” said Samira Sakhia, President and CEO of Knight Therapeutics (KHTRF) Inc.